NASDAQ:DRNA - Dicerna Pharmaceuticals Stock Price, News & Analysis

$14.61
-0.25 (-1.68 %)
(As of 09/15/2019 04:00 PM ET)
Today's Range
$14.51
Now: $14.61
$14.91
50-Day Range
$12.77
MA: $13.88
$15.02
52-Week Range
$9.31
Now: $14.61
$17.98
Volume249,568 shs
Average Volume415,868 shs
Market Capitalization$998.74 million
P/E RatioN/A
Dividend YieldN/A
Beta2.23
Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:DRNA
CUSIPN/A
Phone617-621-8097

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$6.18 million
Book Value$3.20 per share

Profitability

Net Income$-88,850,000.00
Net Margins-737.93%

Miscellaneous

Employees78
Market Cap$998.74 million
Next Earnings Date11/4/2019 (Estimated)
OptionableOptionable

Receive DRNA News and Ratings via Email

Sign-up to receive the latest news and ratings for DRNA and its competitors with MarketBeat's FREE daily newsletter.


Dicerna Pharmaceuticals (NASDAQ:DRNA) Frequently Asked Questions

What is Dicerna Pharmaceuticals' stock symbol?

Dicerna Pharmaceuticals trades on the NASDAQ under the ticker symbol "DRNA."

How were Dicerna Pharmaceuticals' earnings last quarter?

Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) announced its quarterly earnings data on Thursday, August, 8th. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, missing analysts' consensus estimates of ($0.32) by $0.03. The biopharmaceutical company had revenue of $5.68 million for the quarter, compared to analysts' expectations of $10.95 million. Dicerna Pharmaceuticals had a negative net margin of 737.93% and a negative return on equity of 50.30%. View Dicerna Pharmaceuticals' Earnings History.

When is Dicerna Pharmaceuticals' next earnings date?

Dicerna Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, November 4th 2019. View Earnings Estimates for Dicerna Pharmaceuticals.

What price target have analysts set for DRNA?

7 equities research analysts have issued 1-year price targets for Dicerna Pharmaceuticals' shares. Their predictions range from $18.00 to $30.00. On average, they expect Dicerna Pharmaceuticals' share price to reach $23.00 in the next twelve months. This suggests a possible upside of 57.4% from the stock's current price. View Analyst Price Targets for Dicerna Pharmaceuticals.

What is the consensus analysts' recommendation for Dicerna Pharmaceuticals?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dicerna Pharmaceuticals in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Dicerna Pharmaceuticals.

Has Dicerna Pharmaceuticals been receiving favorable news coverage?

News headlines about DRNA stock have been trending somewhat positive this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Dicerna Pharmaceuticals earned a news sentiment score of 0.9 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 1.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Dicerna Pharmaceuticals.

Who are some of Dicerna Pharmaceuticals' key competitors?

What other stocks do shareholders of Dicerna Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Dicerna Pharmaceuticals investors own include Axsome Therapeutics (AXSM), Array Biopharma (ARRY), Strongbridge Biopharma (SBBP), TG Therapeutics (TGTX), Ergomed (ERGO), Arbutus Biopharma (ABUS), Exelixis (EXEL), Equity Commonwealth (EQC), Gilead Sciences (GILD) and Progenics Pharmaceuticals (PGNX).

Who are Dicerna Pharmaceuticals' key executives?

Dicerna Pharmaceuticals' management team includes the folowing people:
  • Dr. Douglas M. Fambrough III, Co-Founder, CEO, Pres & Director (Age 50)
  • Dr. Bob D. Brown, Chief Scientific Officer & Sr. VP (Age 54)
  • Dr. Ralf H. Rosskamp, Chief Medical Officer (Age 66)
  • Dr. Mark Behlke, Co-Founder & Member of Scientific Advisory Board
  • Prof. John J. Rossi, Co-Founder & Chairman of Scientific Advisory Board (Age 72)

Who are Dicerna Pharmaceuticals' major shareholders?

Dicerna Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.25%), UBS Group AG (3.61%), Vanguard Group Inc. (3.42%), Citadel Advisors LLC (3.20%), Price T Rowe Associates Inc. MD (1.69%) and Artal Group S.A. (1.46%). Company insiders that own Dicerna Pharmaceuticals stock include Bain Capital Life Sciences Inv, Brian K Halak, Dennis Langer and James B Weissman. View Institutional Ownership Trends for Dicerna Pharmaceuticals.

Which major investors are selling Dicerna Pharmaceuticals stock?

DRNA stock was sold by a variety of institutional investors in the last quarter, including Sio Capital Management LLC, Bank of America Corp DE, Emerald Mutual Fund Advisers Trust, SG Americas Securities LLC, Emerald Advisers LLC, BNP Paribas Arbitrage SA, Wells Fargo & Company MN and Bank of New York Mellon Corp. Company insiders that have sold Dicerna Pharmaceuticals company stock in the last year include Bain Capital Life Sciences Inv, Brian K Halak and James B Weissman. View Insider Buying and Selling for Dicerna Pharmaceuticals.

Which major investors are buying Dicerna Pharmaceuticals stock?

DRNA stock was bought by a variety of institutional investors in the last quarter, including University of Notre Dame DU Lac, Price T Rowe Associates Inc. MD, Nuveen Asset Management LLC, Citadel Advisors LLC, Alps Advisors Inc., Allianz Asset Management GmbH, Rehmann Capital Advisory Group and UBS Group AG. View Insider Buying and Selling for Dicerna Pharmaceuticals.

How do I buy shares of Dicerna Pharmaceuticals?

Shares of DRNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Dicerna Pharmaceuticals' stock price today?

One share of DRNA stock can currently be purchased for approximately $14.61.

How big of a company is Dicerna Pharmaceuticals?

Dicerna Pharmaceuticals has a market capitalization of $998.74 million and generates $6.18 million in revenue each year. The biopharmaceutical company earns $-88,850,000.00 in net income (profit) each year or ($1.20) on an earnings per share basis. Dicerna Pharmaceuticals employs 78 workers across the globe.View Additional Information About Dicerna Pharmaceuticals.

What is Dicerna Pharmaceuticals' official website?

The official website for Dicerna Pharmaceuticals is http://www.dicerna.com/.

How can I contact Dicerna Pharmaceuticals?

Dicerna Pharmaceuticals' mailing address is 87 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA, 02140. The biopharmaceutical company can be reached via phone at 617-621-8097 or via email at [email protected]


MarketBeat Community Rating for Dicerna Pharmaceuticals (NASDAQ DRNA)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  311 (Thanks for Voting!)
Underperform Votes:  238 (Thanks for Voting!)
Total Votes:  549
MarketBeat's community ratings are surveys of what our community members think about Dicerna Pharmaceuticals and other stocks. Vote "Outperform" if you believe DRNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DRNA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/15/2019 by MarketBeat.com Staff

Featured Article: Portfolio Manager

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel